Primmune Therapeutics Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$23.3M
- Investors
-
9
Primmune Therapeutics General Information
Description
Developer of an orally administered toll-like receptor agonist designed to stimulate innate immunity in cancer immunotherapy. The company's agonist produces cytokines and chemokines that up-regulate general cellular response and facilitate natural killer cell activation, enabling medical practitioners to address all metastatic diseases and stimulate B-cell proliferation and activation.
Contact Information
Website
www.primmunerx.comCorporate Office
- JLABS San Diego
- 3210 Merryfield Row
- San Diego, CA 92121
- United States
Corporate Office
- JLABS San Diego
- 3210 Merryfield Row
- San Diego, CA 92121
- United States
Primmune Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series B) | 26-Jan-2026 | $23.3M | Completed | Clinical Trials - Phase 1 | ||
| 4. Early Stage VC (Series A) | 12-Jan-2021 | Completed | Clinical Trials - Phase 1 | |||
| 3. Seed Round | 02-Mar-2020 | Completed | Clinical Trials - Phase 1 | |||
| 2. Seed Round | 29-Jan-2018 | $1.52M | $1.52M | Completed | Startup | |
| 1. Accelerator/Incubator | 03-Jan-2018 | Completed | Startup |
Primmune Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Series AA2 | ||||||||
| Series AA1 | 1,964,696 | $0.000100 | $0.78 | $0.78 | 1x | $0.78 | 7.97% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Primmune Therapeutics Comparisons
Industry
Financing
Details
Primmune Therapeutics Competitors (67)
One of Primmune Therapeutics’s 67 competitors is Kite Pharma, a Formerly VC-backed company based in Santa Monica, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| Carisma Therapeutics | Formerly VC-backed | Philadelphia, PA | ||||
| Senti Biosciences Holdings | Formerly VC-backed | South San Francisco, CA | ||||
| Instil Bio | Formerly VC-backed | Dallas, TX | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA |
Primmune Therapeutics Patents
Primmune Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220324800-A1 | Sars-3cl protease inhibitors | Inactive | 01-Apr-2021 | ||
| WO-2022212707-A1 | Sars-3cl protease inhibitors | Inactive | 01-Apr-2021 | ||
| JP-2023503996-A | Tlr7 agonist | Active | 26-Nov-2019 | ||
| JP-7777870-B2 | Tlr7 agonist | Active | 26-Nov-2019 | ||
| AU-2020391487-A1 | Tlr7 agonists | Active | 26-Nov-2019 | C07H19/16 |
Primmune Therapeutics Signals
Primmune Therapeutics Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Bioqube Ventures | Venture Capital | Minority | ||
| Oberland Capital | PE/Buyout | Minority | ||
| Polaris Partners | Venture Capital | Minority | ||
| Samsara BioCapital | Venture Capital | Minority | ||
| Biobrit | Venture Capital | Minority |
Primmune Therapeutics FAQs
-
When was Primmune Therapeutics founded?
Primmune Therapeutics was founded in 2017.
-
Where is Primmune Therapeutics headquartered?
Primmune Therapeutics is headquartered in San Diego, CA.
-
What is the size of Primmune Therapeutics?
Primmune Therapeutics has 10 total employees.
-
What industry is Primmune Therapeutics in?
Primmune Therapeutics’s primary industry is Drug Discovery.
-
Is Primmune Therapeutics a private or public company?
Primmune Therapeutics is a Private company.
-
What is Primmune Therapeutics’s current revenue?
The current revenue for Primmune Therapeutics is .
-
How much funding has Primmune Therapeutics raised over time?
Primmune Therapeutics has raised $63.2M.
-
Who are Primmune Therapeutics’s investors?
Bioqube Ventures, Oberland Capital, Polaris Partners, Samsara BioCapital, and Biobrit are 5 of 9 investors who have invested in Primmune Therapeutics.
-
Who are Primmune Therapeutics’s competitors?
Kite Pharma, Carisma Therapeutics, Senti Biosciences Holdings, Instil Bio, and Inovio Pharmaceuticals are some of the 67 competitors of Primmune Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process